Fosun Pharmaceutical: Holds controlling stake in subsidiary's drug approved for clinical trials.

Fosun Pharma announced that its holding subsidiary Fuhong Hanlin has received approval from the National Medical Products Administration to conduct Phase I clinical trials of HLX15-SC for the treatment of multiple myeloma. They plan to conduct relevant clinical studies in China after meeting the necessary conditions. HLX15 is a self-developed biosimilar of daratumumab, and Phase I clinical trials of HLX15-IV were completed in June 2024. As of January 2026, approximately 192 million yuan has been invested in research and development of HLX15. Global sales of daratumumab products were approximately $12.882 billion in 2024. There are uncertainties in drug research and development and market launch.